DSSTox_CID_28975 | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

DSSTox_CID_28975
Health Canada Patents

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

Contact Supplier

Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

Contact Supplier

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Contact Supplier

Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Contact Supplier

DSSTox_CID_28975

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

29 API Suppliers, 6 USDMF, 4 EU WC, 3 NDC API, 23 Listed Suppliers, $ API Reference Price

29 API Suppliers
6 USDMF
4 EU WC
3 NDC API
23 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

121 Drugs in Development

121 Drugs in Development

INTERMEDIATES

19 Intermediate Suppliers

19 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

42 FDF Dossiers, 6 FDA Orange Book, 22 Europe, 2 Canada, 4 Australia, 2 South Africa, 6 Listed Dossiers

42 FDF Dossiers
6 FDA Orange Book
22 Europe
2 Canada
4 Australia
2 South Africa
6 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 2 DKSH, 4 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 5 DFE Pharma, 4 Gangwal Chemicals, 1 Ideal Cures, 1 Ingredion Pharma Solutions, 10 Kerry, 2 Keval Exports, 9 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 1 Pharmatrans-Sanaq, 3 Pluviaendo, 3 Prachin Chemical, 10 Roquette, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 9 Sigachi Industries, 3 Silverline Chemicals, 3 Vasa Pharmachem

1 SPI Pharma
2 DKSH
4 Gangwal Healthcare
1 Nanjing Well Pharmaceutical
4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
1 BASF
5 DFE Pharma
4 Gangwal Chemicals
1 Ideal Cures
1 Ingredion Pharma Solutions
10 Kerry
2 Keval Exports
9 Microlex e.U
2 Nitika Pharmaceutical Specialities
1 Pharmatrans-Sanaq
3 Pluviaendo
3 Prachin Chemical
10 Roquette
3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
9 Sigachi Industries
3 Silverline Chemicals
3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

28 Fillers, Diluents & Binders, 13 Granulation, 13 Direct Compression, 13 Disintegrants & Superdisintegrants, 9 Lubricants & Glidants, 8 Co-Processed Excipients, 8 Thickeners and Stabilizers, 7 Coating Systems & Additives, 4 Film Formers & Plasticizers, 3 Controlled & Modified Release, 3 Chewable & Orodispersible Aids, 3 Taste Masking, 2 Coloring Agents, 2 Rheology Modifiers, 1 Emulsifying Agents, 1 Parenteral

28 Fillers, Diluents & Binders
13 Granulation
13 Direct Compression
13 Disintegrants & Superdisintegrants
9 Lubricants & Glidants
8 Co-Processed Excipients
8 Thickeners and Stabilizers
7 Coating Systems & Additives
4 Film Formers & Plasticizers
3 Controlled & Modified Release
3 Chewable & Orodispersible Aids
3 Taste Masking
2 Coloring Agents
2 Rheology Modifiers
1 Emulsifying Agents
1 Parenteral

DIGITAL CONTENT

77 News #PharmaBuzz

77 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 15 Regulatory FDF Prices, 11 Annual Reports

1 US Medicaid Prescriptions
15 Regulatory FDF Prices
11 Annual Reports

MARKET PLACE

8 APIs

8 APIs

PATENTS & EXCLUSIVITIES

16 US Patents, 12 Health Canada Patents

16 US Patents
12 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 Others

1 Others

$ API Ref.Price (USD/KG) : 453,502 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

12 All

01 12Pfizer Canada ULC

filter Patent Reset all filters

12 All

01 42383630

02 42682859

03 42937521

filter Product Reset all filters

12 All

01 6AXITINIB

02 6Axitinib

filter Dosage Reset all filters

12 All

01 6TABLET

02 6Tablet

filter Exp Date Reset all filters

12 All

01 42020-06-30

02 42028-03-25

03 42035-02-03

Product Main Page

01

Pfizer Canada ULC

Axitinib

NASP

Not Confirmed

Pfizer Canada ULC

NASP

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-06-30

Date Granted : 2008-11-18

Brand Name : INLYTA

Patent Number : 2383630

Filing Date : 2000-06-30

Strength per Unit : 1 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-06-30

Date Granted : 2008-11-18

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Pfizer Canada ULC

Axitinib

NASP

Not Confirmed

Pfizer Canada ULC

NASP

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-06-30

Date Granted : 2008-11-18

Brand Name : INLYTA

Patent Number : 2383630

Filing Date : 2000-06-30

Strength per Unit : 5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-06-30

Date Granted : 2008-11-18

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Pfizer Canada ULC

Axitinib

NASP

Not Confirmed

Pfizer Canada ULC

NASP

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-03-25

Date Granted : 2013-10-08

Brand Name : INLYTA

Patent Number : 2682859

Filing Date : 2008-03-25

Strength per Unit : 1 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2028-03-25

Date Granted : 2013-10-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Pfizer Canada ULC

Axitinib

NASP

Not Confirmed

Pfizer Canada ULC

NASP

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-03-25

Date Granted : 2013-10-08

Brand Name : INLYTA

Patent Number : 2682859

Filing Date : 2008-03-25

Strength per Unit : 5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2028-03-25

Date Granted : 2013-10-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Pfizer Canada ULC

AXITINIB

NASP

Not Confirmed

Pfizer Canada ULC

NASP

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-06-30

Date Granted : 2008-11-18

Brand Name : INLYTA

Patent Number : 2383630

Filing Date : 2000-06-30

Strength per Unit : 3 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2020-06-30

Date Granted : 2008-11-18

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Pfizer Canada ULC

AXITINIB

NASP

Not Confirmed

Pfizer Canada ULC

NASP

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-03-25

Date Granted : 2013-10-08

Brand Name : INLYTA

Patent Number : 2682859

Filing Date : 2008-03-25

Strength per Unit : 3 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2028-03-25

Date Granted : 2013-10-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

Pfizer Canada ULC

AXITINIB

NASP

Not Confirmed

Pfizer Canada ULC

NASP

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-03-25

Date Granted : 2013-10-08

Brand Name : INLYTA

Patent Number : 2682859

Filing Date : 2008-03-25

Strength per Unit : 7 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2028-03-25

Date Granted : 2013-10-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

Pfizer Canada ULC

AXITINIB

NASP

Not Confirmed

Pfizer Canada ULC

NASP

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-06-30

Date Granted : 2008-11-18

Brand Name : INLYTA

Patent Number : 2383630

Filing Date : 2000-06-30

Strength per Unit : 7 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2020-06-30

Date Granted : 2008-11-18

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

Pfizer Canada ULC

Axitinib

NASP

Not Confirmed

Pfizer Canada ULC

Country

NASP

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2035-02-03

Date Granted : 2023-08-29

Brand Name : INLYTA

Patent Number : 2937521

Filing Date : 2015-02-03

Strength per Unit : 1 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2035-02-03

Date Granted : 2023-08-29

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

10

Pfizer Canada ULC

Axitinib

NASP

Not Confirmed

Pfizer Canada ULC

Country

NASP

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2035-02-03

Date Granted : 2023-08-29

Brand Name : INLYTA

Patent Number : 2937521

Filing Date : 2015-02-03

Strength per Unit : 5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2035-02-03

Date Granted : 2023-08-29

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!